ORCHIDPHAR

Accordingly the balance 80,000 warrants pending for conversion in the name of Dr M R Girinath at a price of Rs. 339.41 per share were adjusted for the issue of 1,20,000 warrants at an adjusted price of Rs. 226.28 per share. Pursuant to the conversion of warrants by the holder, 50,000 shares out of the 1,20,000 warrants were allotted to Dr M R Giririath on March 20, 2006. Consequent to these allotments, the paid-up capital of the Company has increased from Rs. 62,15,06,260 to Rs. 63,03,01,150.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Orchid on March 20, 2006 have allotted 921,657 equity shares of Rs.10 each arising out of conversion of Zero Coupon Foreign Currency Convertible Bonds aggregating US$ 5,000,000 to M/s. Grants Investment Limited. These shares have been issued at a price of Rs. 243.80 per share (price equivalent to US$ 5.425 per share) in accordance with the terms of the FCCB issue made by the Company during November 2005. Consequent to these allotments the paid-up capital of the Company has increased to

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Dr. I Seetharam Naidu, Director has sold 10,000 shares on March 10, 2006. The shareholding of I Seetharam Naidu after the said sale is 3,77,280 shares aggregating to 0.61% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of the Company at their meeting held on March 07, 2006 have allotted 4,60,827 equity shares of Rs.10/- each arising out of conversion of zero Coupon Foreign Currency Convertible Bonds aggregating US$ 2,500,000 to M/s. Plexus Fund Limited. These shares have been issued at a price of Rs.243.80 per share (price equivalent to US$ 5.425 per share) in accordance with the terms of the FCCB issue made by the Company during November 2005. Consequent to this allotment, the paid-up capi

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of Board of Directors of the Company at their meeting held on March 01, 2006 have allotted 1,84,330 equity shares of Rs.10/- each arising out of conversion of Zero Coupon Foreign Currency Convertible Bonds aggregating US$ 1,000,000 to M/s. Plexus Fund Limited. These shares have been issued at a price of Rs.243.80 per share (price equivalent to US$ 5.43 per share) in accordance with the terms of the FCCB/GDR issue made by the Company during November 2005. Consequent to this allotment, the paid-up capit

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that I Seetharam Naidu, Director has sold 8,000 shares on February 23, 2006 and February 24, 2006. The shareholding of I Seetharam Naidu after the said sale is 3,87,280 shares aggregating to 0.63% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that I Seetharam Naidu has sold 12,000 shares on February 15, 2006. The shareholding of I Seetharam Naidu after the said sale is 3,96,280 shares aggregating to 0.64% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has entered into a long-term Master Research & Development agreement with Pfizer International, LLC for providing research and development services to Pfizer's Animal Health business. A copy of the Press Release issued by the company on February 16, 2006 regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefoxitin for Injection, 10 g/vial (Pharmacy Bulk Package).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that I Seetharam Naidu has sold 2000 shares on February 03, 2006. The shareholding of I Seetharam Naidu after the said sale is 4,08,280 shares aggregating to 0.66% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefoxitin for injection, 1gm/vial and 2gm/vial. A copy of the Press Release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Right On Time Limited has informed the Exchange that they have sold 37,93,935 shares aggregating to 6.16% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd during the period January 12, 2006 to January 19, 2006. The shareholding of Right On Time Limited after the said sale is 1,000,000 shares aggregating to 1.63% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Right On Time Limited ("Seller") has sold 37,93,935 shares aggregating to 6.16% of the total paid up capital of Orchid Chemicals & Pharmaceuticals Ltd during the period January 12, 2006 to January 19, 2006. The mode of sale is Open Market Sale and the shareholding of Right On Time Limited after the said sale is 10,00,000 shares aggregating to 1.62% of the total paid up capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated January 19, 2006, titled "Orchid registers turnover of Rs.238 crore during Q3 FY 2005-06 - Net profit jumps by 402% to Rs.29 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefprozil for Oral Suspension USP, 125mg/5ml and 250mg/5 ml. A press release, dated, January 02, 2006, titled, "Orchid receives USFDA approval for Cefprozil oral suspension ANDA" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Board of Directors of the company at its meeting held on December 23, 2005 have allotted 19,649 equity shares of Rs. 10 each to the employees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefprozil Tablets USP 250mg and 500mg. The approval of USFDA for the ANDA would enable the Company to launch the product in the US. A copy of the Press Release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated December 02, 2005 titled, "His Excellency The President of India visits Orchid's state-of-the-art formulations manufacturing complex; Addresses scientists and staff on drug discovery opportunity". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Raj Rajkumar has acquired shares of Orchid Chemicals & Pharmaceuticals Ltd as follows: (1) On November 16, 2005 - 20,000 shares; (2) On November 22, 2005 - 16,000 shares and (3) On November 23, 2005 - 4,000 shares. The mode of acquisition is Market purchase and the shareholding of Raj Rajkumar after the said acquisition is 40,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited in their meeting held on November 29, 2005, have allotted 6,00,000 additional Global Depository Receipts (being the green shoe option) at a price of US$ 4.34 per GDR (equivalent to Rs.195.04 per share), each GDR representing one underlying equity share of Orchid at a nominal value of Rs. 10 per share to M/s. Citibank, N.A., New York. For the above Issue, M/s. Citigroup Global Markets Limited, UK were the sole bookrunners.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the promoter Shri K Raghavendra Rao has purchased 60,000 equity shares of Rs. 10/- each of the Company from the secondary market. Consequent to this purchase, Shri K Raghavendra Rao holds 66,15,173 equity shares of the Company constituting 10.86% of the total capital of the Company.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the BODs of the Company held on October 13, 2005, have allotted 105,000 equity shares of Rs.10/- each arising out of the conversion of 70,000 warrants out of the total 20,00,000 warrants issued on private placement basis to Mrs. R Vijayalakshmi (W/o Shri K Raghavendra Rao, Managing Director & Promoter of the Company). The Company has further informed that the members of the Company at an EGM held on August 18, 2005 have approved an issue of bonus share(s) in the proportion of one equity share of Rs

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that pursuant to the issue of bonus share(s) in the proportion of one equity share for every two equity shares of Rs.10/- each held, the number and price of un-converted warrants and un-exercised Employees Stock Options have been adjusted by the Board. Due to the above corporate action, the Board at its meeting held on October 13, 2005 approved an adjustment in the number and price of warrants, by multiplying the un-converted warrants by 3/2 and the price at which each warrant to be subscribed by 2/3. The number and price of war

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited held on November 02, 2005, have allotted 8,650,000 Global Depository Receipts at a price of US$ 4.34 per GDR (equivalent to Rs.195 per share), each GDR representing one underlying equity share of Orchid at a nominal value of Rs. 10 per share to M/s. Citibank, N.A., New York. Further, the Allotment Committee of the Board has allotted Zero Coupon Foreign Currency Convertible Bonds due 2010 (FCCBs), aggregating US$ 37,500,000 (US$ th

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the promoter Shri K Raghavendra Rao has purchased 2,75,000 equity shares of Rs. 10/- each of the Company from the secondary market. Consequent to this purchase, Shri K Raghavendra Rao holds 65,55,173 equity shares of the Company constituting 10.77% of the total capital of the Company.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that there was an incident of fire in a solvent recovery block at around 8.30 P.M on November 03, 2005 in Orchid's API drug manufacturing facility at Alathur, near chennai. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that HSBC Global Investment Fund along with PAC: HSBC Investments (Hong Kong) Limited has acquired 4,600,000 GDRs aggregating to 7.57% of the total share capital of the Orchid Chemicals & Pharmaceuticals Ltd on October 28, 2005. The mode of acquisition is through GDRs Offering and the shareholding of HSBC Global Investments Fund along with PAC: HSBC Investments (Hong Kong) Limited after the said acquisition is 4,600,000 GDRs of Orchid Chemicals & Pharmaceuticals Ltd.

HSBC Investments (Hongkong) Limited has informed the Exchange that HSBC Global Investment Funds - A/C HSBC Global Investment Funds (Mauritius) Limited alongwith HSBC Investments (Hongkong) Limited (PAC) has acquired 46,00,000 shares of Orchid Chemicals & Pharmaceuticals Limited on October 28, 2005. The mode of acquisition is through GDRs Offering and the shareholding of HSBC Global Investment Funds - A/ C HSBC Global Investment Funds (Mauritius) Limited alongwith HSBC Investments (Hongkong) Limited (PAC) after the said acquisition is 46,00,000 shares aggregating to 7.57% of the total paid up c

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the company has isseud a press release in respect of the issue of Global Depository Receipts (GDR's) and Foreign Currency Convertible Bonds (FCCB's) aggregating US$ 75 million. The said securities is proposed to be listed in the Luxembourg Stock Exchange. The details of the press shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated October 13, 2005 titled 'Orchid's Q2 net zooms by 587%; Step function increases in turnover and profitability with regulated market thrust'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release being issued on October 04,2005 in respect of the company's exclusive marketing alliance with Mayne Pharma to market select life-saving injectable antibiotic formulation in the US,Canada,European and Australasian geographies. The details of the press release titled 'Orchid enters into exclusive marketing alliance with Mayne Pharma ; Broad-based global alliance covering select niche injectable products' shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcement

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that pursuant to the approval accorded by the shareholders at the EGM held on August 18,2005 the Allotment Committee of the BOD's of the Company at its meeting held on September 21, 2005 have allotted 1,73,76,940 equity shares of Rs.10 each, fully paid-up, to the shareholder of the Company as on the record date i.e. September 17, 2005. Further, the Company has informed the Exchange that the Bonus Equity Shares allotted shall rank pari-passu in all respects with the existing shares of the Company.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the BOD's of the Company at its meeting held on August 31, 2005 has allotted 300,676 equity shares of Rs.10 each (185,084 shares at Rs.243.35 per share and 115,592 shares at Rs.252/- per share) to the employees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that further to the allotment of 25,00,000 warrants on private placement basis to promoter/promoter group made on August 02,2005,the Allotment committee of the BODs of Orchid Chemicals & Pharmaceuticals Limited on August 31, 2005, have allotted 70,000 equity shares of Rs.10/- each arising out of the conversion of 70,000 warrants, to Dr Maligail Ramakrishna Girinath.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the shareholders of the Company have approved the issue of Bonus Equity Shares in the proportion of one equity share of Rs.10 each for every two equity shares of Rs.10 each, at an EGM held on August 18, 2005. Further, the Board has decided to fix the Record date for the purpose of bonus issue as September 17, 2005. A copy of the resolution passed by the Shareholders at the EGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate

K Raghavendra Rao has informed the Exchange that M/s Orchid Chemicals & Pharmaceuticals Limited have on August 02, 2005, allotted 130000 equity shares of Rs.10 each arising out of the conversion of 130000 (out of the total allotted warrants of 950000) warrants issued on private placement basis to Mrs. R Vijayalakshmi. Subsequent, to the above allotment, the aggregate share holding of K Raghavendra Rao along with persons acting in concert, Mrs. R Vijayalakshmi and M/s. Orchid Health Care Private Limited have increased from 66,20,310 shares to 67,50,310 shares in the total share capital of the C

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that R. Vijayalakshmi, K. Raghavendra Rao, Orchid Health Care Private Limited (PAC) have acquired 130,000 shares aggregating to 0.23% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd on August 02, 2005. The mode of acquisition is Conversion of warrants into Equity Shares and the shareholding of Vijayalakshmi, K. Raghavendra Rao, Orchid Health Care Private Limited (PAC) after the said acquisition is 6750310 shares aggregating to 19.63% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Management Team of the Company made a presentation on the Profile & Strategy of the Company to Analysts on August 09, 2005 and the same has been uploaded in the Company's website www.orchidpharma.com.

Orchid Health Care Private Limited has informed the Exchange that Orchid Chemicals & Pharmaceuticals Ltd on August 02, 2005 have allotted 1,30,000 equity shares of Rs.10 each arising out of the conversion of 1,30,000(out of the total allotted warrants of 9,50,000) warrants issued on private placement basis to Mrs. R. Vijayalakshmi. Subsequent to this allotment, the aggregate shareholding of Orchid Health Care Pvt.Ltd. along with persons acting in concert, Mrs. R. Vijayalakshmi amd Mr. K. Raghavendra Rao have increased from 66,20,310 shares to 67,50,310 shares in the total share capital of M/

R. Vijayalakshmi has informed the Exchange that Orchid Chemicals & Pharmaceuticals Ltd on August 02, 2005 have allotted 1,30,000 equity shares of Rs.10 each arising out of the conversion of 1,30,000 (out of the total alloted warrants of 9,50,000) warrants issued on private placement basis .Subsequent to this allotment, her holding in the Company has increased from 8,08,918 shares to 9,38,918 shares (from 2.37% to 2.73% on the total share capital).

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of Proceedings of the AGM of the Company held on July 18, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment committee of the BODs of the company on August 02, 2005, have allotted 25,00,000 (twenty five lakh only) Warrants convertible into equity to the following persons. Each warrant is convertible into one equity shares of Rs.10/- each within eighteen months from the date of Allotment, at a price of Rs. 339.41 (Rupees three hundred and thirty nine and forty one paise only). Promoter/Promoter Group: Mrs. R Vijayalakshmi (W/o Shri K Raghavendra Rao, Managing Director & Promoter of the Company) - 23,50,000 equity share

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that an EGM of the Members of the Company will be held on August 18, 2005. The details of the EGM Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment committee of the BOD's of the company on August 02, 2005, have allotted 25,00,000 warrants convertible into equity to the following persons: 1) Promoter/Promoter Group: Mrs. R Vijayalakshmi (W/o Shri K Raghavendra Rao, Managing Director & Promoter of the Company) - 23,50,000 Warrants; 2) Dr. M R Grininath - 1,50,000 warrants. Each warrant is convertible into one equity share of Rs.10 each within eighteen months from the date of allotment, at a price of Rs.339.41.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has received the formal approval from the USFDA for its generic Abbreviated New Drug Application (ANDA) for its formulation product Ceftriaxone for Injection USP, in 250 mg, 500 mg, 1 gm and 2 gm single-dose vials, 1 gm and 2 gm piggyback vials and 10 gm/100 ml pharmacy bulk package vials. The approval of USFDA for the ANDA enables the Company to launch the product in the US. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) u

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the BOD's of the Company at its meeting held on August 02, 2005 have allotted 59,485 equity shares of Rs.10 each (44,320 shares at Rs.243.35 per share and 15,165 shares at Rs.252/- per share) to the employees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment committee of the BOD's of the company on August 02, 2005, have allotted 180,000 equity shares of Rs.10/- each arising out of the conversion of 180,000 warrants issued on private placement basis to the following persons: 1) Promoter/Promoter Group: Mrs. R Vijayalakshmi (W/o Shri K Raghavendra Rao, Managing Director & Promoter of the Company) - 130,000 equity shares; 2) Dr. I Seetharam Naidu - 50,000 equity shares.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Board at its meeting held on July 18, 2005, have approved an issue of Bonus shares to the shareholders in the ratio of one bonus share for every two shares held.

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the press release issued by the Company pursuant to the meeting of the BOD's of the Company held on July 18, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that an AGM of the Members of the Company will be held on July 18, 2005. The details of the AGM Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).